{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=10",
    "query": {
      "condition": "Congenital Defects",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 10850,
    "total_pages": 1085,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T15:31:33.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07024693",
      "title": "DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fuchs Endothelial Corneal Dystrophy",
        "Fuchs"
      ],
      "interventions": [
        {
          "name": "DT-168",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Design Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-07-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07024693"
    },
    {
      "nct_id": "NCT04219007",
      "title": "Vosoritide for Selected Genetic Causes of Short Stature",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Short Stature"
      ],
      "interventions": [
        {
          "name": "Vosoritide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Dauber",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "3 Years to 10 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-08-04",
      "completion_date": "2035-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04219007"
    },
    {
      "nct_id": "NCT06253507",
      "title": "pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "p47",
        "Autosomal Recessive",
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "3 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-06-25",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06253507"
    },
    {
      "nct_id": "NCT07367971",
      "title": "Drug-Drug Interaction Study of ABP-671 in Gout Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gout Chronic",
        "Gout",
        "DDI (Drug-Drug Interaction)"
      ],
      "interventions": [
        {
          "name": "ABP-671 plus allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atom Therapeutics Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 22,
      "start_date": "2026-01-23",
      "completion_date": "2026-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 1,
      "location_summary": "Cary, North Carolina",
      "locations": [
        {
          "city": "Cary",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07367971"
    },
    {
      "nct_id": "NCT00304512",
      "title": "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "migalastat HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2006-09-07",
      "completion_date": "2008-05-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304512"
    },
    {
      "nct_id": "NCT00968565",
      "title": "Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Heart Defects, Congenital",
        "Respiratory Insufficiency"
      ],
      "interventions": [
        {
          "name": "sodium citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "1 Day to 1 Year"
      },
      "enrollment_count": 2,
      "start_date": "2010-01",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968565"
    },
    {
      "nct_id": "NCT06467344",
      "title": "Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Cone Rod Dystrophy",
        "Juvenile Macular Degeneration",
        "Stargardt Disease 1"
      ],
      "interventions": [
        {
          "name": "ACDN-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascidian Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-06-11",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Gainesville, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06467344"
    },
    {
      "nct_id": "NCT02900144",
      "title": "Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tourette Syndrome",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Modified Comprehensive Behavioral Intervention for Tics",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Comprehensive Behavioral Intervention for Tics",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-09",
      "completion_date": "2019-04-10",
      "has_results": false,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900144"
    },
    {
      "nct_id": "NCT03614234",
      "title": "Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "pegunigalsidase alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2018-11-13",
      "completion_date": "2026-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03614234"
    },
    {
      "nct_id": "NCT03848832",
      "title": "Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rett Syndrome",
        "RTT"
      ],
      "interventions": [
        {
          "name": "GWP42003-P",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 29,
      "start_date": "2019-07-29",
      "completion_date": "2021-01-21",
      "has_results": true,
      "last_update_posted_date": "2022-09-02",
      "last_synced_at": "2026-11-19T15:31:33.818Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848832"
    }
  ]
}